BPC-157: What the Research Actually Shows About Gut Healing and Tissue Repair

BPC-157, or Body Protection Compound-157, is a synthetic pentadecapeptide derived from a protective protein found in human gastric juice. It has become one of the most widely discussed peptides in regenerative and gastrointestinal research circles. But what does the published evidence actually support? This review, compiled by the Peptide Register as part of its independent research reference library, examines the available data with full transparency about evidence quality and limitations.

What Is BPC-157 and How Does It Work?

BPC-157 is a 15-amino-acid peptide that does not occur naturally in isolation. It is a fragment of a larger protein identified in gastric juice, and the synthetic version used in research is referred to as a "stable gastric pentadecapeptide." BPC-157 is a synthetic pentadecapeptide consisting of 15 amino acids derived from a human gastric juice protein.

The proposed mechanisms of action span multiple pathways. Preclinical studies suggest BPC-157 may interact with the nitric oxide (NO) system, promote angiogenesis (the formation of new blood vessels), and modulate growth factor expression. Some researchers have also proposed interactions with the dopaminergic system and the FAK-paxillin signalling pathway, which is involved in cell migration and adhesion. For readers less familiar with peptide classification, our overview of how peptides differ from proteins, hormones, and small molecules provides useful context.

It is important to note that these mechanistic proposals are drawn primarily from in vitro and animal models. BPC-157's proposed mechanisms of action, including nitric oxide modulation and angiogenesis promotion, are derived primarily from animal models.

Animal Study Evidence: Gut and Tissue Repair

The bulk of BPC-157 research has been conducted in rodent models. Published animal studies on BPC-157 number in the hundreds, spanning gastrointestinal, musculoskeletal, and neurological injury models. In gastrointestinal research, studies in rats have reported accelerated healing of gastric ulcers, reduced inflammation in models of inflammatory bowel disease, and protective effects against NSAID-induced gut damage. Animal studies have reported that BPC-157 accelerated gastric ulcer healing and reduced inflammation in rodent models of inflammatory bowel disease.

In musculoskeletal contexts, rodent studies have reported faster healing of tendons, ligaments, and muscle tissue following injury. One frequently cited study observed accelerated Achilles tendon healing in rats, with histological evidence of improved collagen organization. Rodent studies have also reported that BPC-157 promoted faster tendon and ligament healing with improved collagen organization.

Additional rodent research has explored BPC-157 in models of bone fracture, skin wound healing, and corneal injury, generally reporting positive outcomes. Some studies have also examined its effects on the central nervous system, including models of traumatic brain injury and peripheral nerve damage.

However, these findings carry significant caveats. The vast majority of BPC-157 research has been conducted by a relatively small number of research groups, primarily based at the University of Zagreb. The majority of published BPC-157 studies originate from a small number of research groups, primarily at the University of Zagreb. Independent replication by other laboratories remains limited, which is a meaningful gap in the evidence base. For guidance on interpreting these kinds of studies, our post on how to read peptide research offers a practical framework.

Human Evidence: Where Are the Clinical Trials?

This is the most significant limitation in the BPC-157 evidence base. As of mid-2025, no large-scale, peer-reviewed, randomized controlled trials of BPC-157 in humans have been published. As of 2025, no large-scale randomized controlled trials of BPC-157 in humans have been published in peer-reviewed journals. A small number of pilot studies and case reports exist, but they lack the statistical power and controlled design needed to draw firm conclusions about efficacy or safety in humans.

The absence of robust human trial data means that all claims about BPC-157's effects on gut healing or tissue repair in humans remain extrapolations from animal research. The gap between animal findings and human clinical evidence is a recurring theme in peptide science, as discussed in the context of the growing divide between peptide research and regulatory policy.

Long-term safety data for BPC-157 in humans is also absent, and potential risks remain poorly characterized. BPC-157 lacks published long-term safety data in humans, and its risk profile remains poorly characterized.

Regulatory Status and Access

BPC-157 is not approved by the FDA for any therapeutic indication in the United States. In 2023, the FDA placed BPC-157 on its Category 2 list, indicating insufficient safety data for compounding. BPC-157 is not approved by the FDA for any therapeutic use and was placed on the FDA Category 2 list in 2023. In Australia, BPC-157 falls under Schedule 4 prescription-only classification through the TGA. It is not approved as a registered therapeutic good. Access in the UK and EU is similarly restricted, with no regulatory approval for clinical use.

The grey market availability of BPC-157 is widespread, which raises concerns about product purity, contamination, and lack of clinical oversight. The Peptide Register's grey market monitoring resource tracks these dynamics independently.

Summary of the Evidence

BPC-157 has generated a substantial preclinical evidence base suggesting potential effects on gut healing, tissue repair, and cytoprotection. However, the evidence remains almost entirely limited to animal models, with limited independent replication and no published large-scale human trials. Researchers and clinicians should interpret the existing data with appropriate caution, recognizing the distance between promising animal findings and validated human therapeutic applications. The Peptide Register will continue to update its BPC-157 profile as new peer-reviewed data becomes available.